Highlights
- •Drug-related interstitial lung disease (ILD)/pneumonitis diagnosis is challenging.
- •Careful monitoring, prompt diagnosis, and appropriate management are important.
- •Most events are low grade and can be managed safely.
- •Education is critical to ensure potential ILD/pneumonitis is proactively identified.
- •We suggest using a multidisciplinary approach.
Abstract
Search strategy and selection criteria
Introduction
Background on trastuzumab deruxtecan

Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Primary analysis of a phase 2 single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. Presented at: ESMO Congress; September 16-21, 2021.
ClinicalTrials.gov. A phase 2 study of T-DXd in patients with selected HER2 expressing tumors (DPT02). https://clinicaltrials.gov/ct2/show/NCT04482309 (accessed May 25 2021).
ClinicalTrials.gov. A Study of T-DXd for the treatment of solid tumors harboring HER2 activating mutations (DPT01). https://clinicaltrials.gov/ct2/show/NCT04639219 (accessed May 19 2021).
ClinicalTrials.gov. Trastuzumab deruxtecan in participants with HER2-overexpressing advanced or metastatic colorectal cancer (DESTINY-CRC02). https://clinicaltrials.gov/ct2/show/NCT04744831 (accessed May 19 2021).
ClinicalTrials.gov. Trastuzumab deruxtecan (DS-8201a) versus investigator's choice for HER2-low breast cancer that has spread or cannot be surgically removed [DESTINY-Breast04]. https://clinicaltrials.gov/ct2/show/NCT03734029 (accessed May 19 2021).
ClinicalTrials.gov. Study of trastuzumab deruxtecan (T-DXd) vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer (DB-06). https://clinicaltrials.gov/ct2/show/NCT04494425 (accessed May 19 2021).
ClinicalTrials.gov. Trastuzumab deruxtecan (T-DXd) with or without pertuzumab versus taxane, trastuzumab and pertuzumab in HER2-positive metastatic breast cancer (DESTINY-Breast09). https://clinicaltrials.gov/ct2/show/NCT04784715 (accessed June 3 2021).
ClinicalTrials.gov. Ph1b/2 study of the safety and efficacy of T-DXd combinations in advanced HER2+ gastric cancer (DESTINY-Gastric03) (DG-03). https://clinicaltrials.gov/ct2/show/NCT04379596 (accessed June 10 2021).
Study | Number of Patients | Patient Population | ORR by ICR (95% CI), % | Most Common Grade ≥ 3 Adverse Events (% of Patients) | Any Grade ILD, n (%) | Grade 1 or 2 ILD, n (%) | Grade 3 ILD, n (%) | Grade 4 ILD, n (%) | Grade 5 ILD, n (%) | |
---|---|---|---|---|---|---|---|---|---|---|
DESTINY-Breast01 (NCT03248492) 5 , | 184 | T-DM1–treated, HER2-positive unresectable or metastatic breast cancer | 62.0 (54.5–69.0) | Decreased neutrophil count (20.7), anemia (8.7), and nausea (7.6) | 29 (15.8) | 23 (12.5) | 1 (0.5) | 0 | 5 (2.7) | |
DESTINY-Breast03 (NCT03529110) [7] | T-DXd arm | 261 | HER2-positive unresectable or metastatic breast cancer | 79.7 (74.3–84.4) | Neutropenia (19.1), thrombocytopenia (7.0), leukopenia (6.6), and nausea (6.6) | 27 (10.5) | 25 (9.7) | 2 (0.8) | 0 | 0 |
T-DM1 arm | 263 | HER2-positive unresectable or metastatic breast cancer | 34.2 (28.5–40.3) | Thrombocytopenia (24.9), AST increased (5.0), and ALT increased (4.6) | 5 (1.9) | 5 (1.9) | 0 | 0 | 0 | |
DESTINY-Gastric01 (NCT03329690) [8] | T-DXd arm | 125 | HER2-positive locally advanced or metastatic gastric/GEJ cancer | 43 (34–52) | Decreased neutrophil count (51.2), anemia (37.6), and decreased white cell count (20.8) | 12 (9.6) | 9 (7.2) | 2 (1.6) | 1 (0.8) | 0 |
Chemotherapy arm | 62 | HER2-positive locally advanced or metastatic gastric/GEJ cancer | 12 (5–24) | Decreased neutrophil count (24.2), anemia (22.6), and decreased appetite (12.9) | 0 | 0 | 0 | 0 | 0 | |
DESTINY-Gastric02 (NCT04014075) [9] Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Primary analysis of a phase 2 single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. Presented at: ESMO Congress; September 16-21, 2021. | 79 | HER2-positive unresectable or metastatic gastric/GEJ cancer | 38 (27.3–49.6) | Anemia (7.6) and decreased neutrophil count (7.6) | 6 (7.6) | 5 (6.3) | 0 | 0 | 1 (1.3) | |
DESTINY-Lung01 (NCT03505710) 6 , 93 | 91 | HER2-mutant unresectable or metastatic NSCLC | 55 (44–65) | Decreased neutrophil count (18.7), anemia (9.9), and nausea (8.8) | 24 (26.4) | 18 (19.8) | 4 (4.4) | 0 | 2 (2.2) | |
49 | HER2-overexpressing unresectable/metastatic NSCLC | 24.5 (13.3–38.9) | Decreased neutrophil count (20.4) | 8 (16.3) | 5 (10.2) | 0 | 0 | 3 (6.1) |
Pathophysiology and etiology of ILD
- Travis W.D.
- Costabel U.
- Hansell D.M.
- King T.E.
- Lynch D.A.
- Nicholson A.G.
- et al.
- Travis W.D.
- Costabel U.
- Hansell D.M.
- King T.E.
- Lynch D.A.
- Nicholson A.G.
- et al.
ILD/pneumonitis associated with anticancer treatments
- Okada N.
- Matsuoka R.
- Sakurada T.
- Goda M.
- Chuma M.
- Yagi K.
- et al.
ClinicalTrials.gov. Ph1b/2 study of the safety and efficacy of T-DXd combinations in advanced HER2+ gastric cancer (DESTINY-Gastric03) (DG-03). https://clinicaltrials.gov/ct2/show/NCT04379596 (accessed June 10 2021).
ClinicalTrials.gov. DS8201a and pembrolizumab in participants with locally advanced/metastatic breast or non-small cell lung cancer. https://clinicaltrials.gov/ct2/show/NCT04042701 (accessed February 17 2022).
ClinicalTrials.gov. A phase 1b/2 study of T-DXd combinations in HER2-positive metastatic breast cancer (DB-07). https://clinicaltrials.gov/ct2/show/NCT04538742 (accessed February 17 2022).
ClinicalTrials.gov. A phase 1b study of T-DXd combinations in HER2-low advanced or metastatic breast cancer (DB-08). https://clinicaltrials.gov/ct2/show/NCT04556773 (accessed February 17 2022).
ClinicalTrials.gov. A study of novel anti-cancer agents in patients with metastatic triple negative breast cancer (BEGONIA). https://clinicaltrials.gov/ct2/show/NCT03742102 (accessed February 17 2022).
ClinicalTrials.gov. Phase Ib study of the safety of T-DXd and durvalumab with chemotherapy in advanced or metastatic HER2+ non-squamous NSCLC (DL03). https://clinicaltrials.gov/ct2/show/NCT04686305 (accessed February 17 2022).
ClinicalTrials.gov. Phase II umbrella study of novel anti-cancer agents in patients with NSCLC who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON). https://clinicaltrials.gov/ct2/show/NCT03334617 (accessed February 17 2022).
T-DXd–related ILD/pneumonitis
Preclinical data
Adjudication committee for clinical trials
Clinical data
Pooled Analysis | ||
---|---|---|
Powell et al. 2021 [66] (N = 879) | Yin et al. 2021 [69] (N = 645) b Data cutoffs for the studies included in this analysis were February 1, 2019 for J101; December 5, 2018 for J102; September 14, 2018 for A103; September 26, 2018 for A104; and March 21, 2019 for DESTINY-Breast01. Six patients were excluded from the exposure-safety analysis for missing PK samples (n = 3) and protocol deviation for taking prohibited medication (n = 3). | |
Studies | DS8201-A-J101, DS8201-A-J102, DS8201-A-A103, DS8201-A-A104, DESTINY-Breast01, DESTINY-CRC01, DESTINY-Lung01, and DESTINY-Gastric02 | DS8201-A-J101, DS8201-A-J102, DS8201-A-A103, DS8201-A-A104, and DESTINY-Breast01 |
Tumor types | Multiple types of HER2-expressing or HER2-positive unresectable or metastatic tumors, including breast, gastric, lung, and colorectal; HER2-mutant lung cancer | Multiple types of HER2-expressing or HER2-positive unresectable and/or metastatic tumors, including breast and gastric |
T-DXd doses | 5.4, 6.4, 7.4, or 8.0 mg/kg q3w | 0.8, 1.6, 3.2, 5.4, 6.4, 7.4, or 8.0 mg/kg q3w |
Number of prior regimens, median (range) | 5.0 (1–27) | NR |
Japanese, n (%) | 364 (41.4) | 312 (49) |
Patients with ILD/pneumonitis, n (%) | 139 (15.8) | 70 (11) |
Grade 1 | 40 (4.6) | NR |
Grade 2 | 68 (7.7) | NR |
Grade ≥ 3 | 31 (3.5) | 18 (3) |
Grade 3 | 9 (1.0) | NR |
Grade 4 | 1 (0.1) | NR |
Grade 5 | 21 (2.4) | NR |
Factors of interest potentially associated with ILD/pneumonitis | Treatment in Japan vs non-Japan countries; T-DXd dose of ≥ 7.4 vs 5.4 mg/kg; baseline SpO2 of < 95% vs ≥ 95%; moderate/severe renal impairment at baseline vs no impairment; presence of certain lung comorbidities (yes vs no: asthma, COPD, prior ILD/pneumonitis, pulmonary fibrosis, pulmonary emphysema, or radiation pneumonitis); and time since initial diagnosis (≥ 3.9 vs < 3.9) years | Asian-Japan race-country group (probability of discontinuation associated with ILD: 0.206) and T-DXd dose of 6.4 vs 5.4 mg/kg (incidence of any-grade ILD: 17.0% [90% CI, 14.8%–19.2%] vs 14.0% [90% CI, 11.5%–15.6%]) d The Asian-Japan race-country covariate group was identified by an exposure-safety analysis that used a Cox proportional hazards regression model; ILD grade ≥ 3 specifically was not found to be associated with any covariates; all-grade ILD was associated with Asian-Japan race-country covariate group. Covariates in this analysis included race (Asian vs White vs other) and country (Japan vs non-Japan), which were correlated and combined into a single race/country covariate. T-DXd dose was identified by a dose–response projection analysis that used the model developed in the exposure–response analysis. |
Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Primary analysis of a phase 2 single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. Presented at: ESMO Congress; September 16-21, 2021.

Characterizing patients who have developed ILD/pneumonitis
- Suh C.H.
- Park H.S.
- Kim K.W.
- Pyo J.
- Hatabu H.
- Nishino M.
Monitoring and diagnosis of ILD/pneumonitis in patients receiving T-DXd
Patient and provider education on T-DXd–related ILD/pneumonitis
Proactive patient monitoring
Recommendations | |
---|---|
Prior to starting treatment with T-DXd [11] |
|
Provider education |
|
Patient education |
|
Proactive patient monitoring |
|
Multidisciplinary diagnosis

Multidisciplinary management of T-DXd–related ILD/pneumonitis
- Puzanov I.
- Diab A.
- Abdallah K.
- Bingham C.O.
- Brogdon C.
- Dadu R.
- et al.
Grade 1 ILD/pneumonitis
- Puzanov I.
- Diab A.
- Abdallah K.
- Bingham C.O.
- Brogdon C.
- Dadu R.
- et al.
Grade 2 ILD/pneumonitis
Grade 3 or 4 ILD/pneumonitis
- Puzanov I.
- Diab A.
- Abdallah K.
- Bingham C.O.
- Brogdon C.
- Dadu R.
- et al.
Future directions
Mechanisms underlying T-DXd–related ILD/pneumonitis
Areas for future innovation
- Krauss E.
- Haberer J.
- Maurer O.
- Barreto G.
- Drakopanagiotakis F.
- Degen M.
- et al.
Interstitial Lung Disease. ATS clinical practice guidelines & statements. https://www.thoracic.org/education-center/ild/resources.html (accessed February 22 2022).
Areas for future T-DXd–related ILD/pneumonitis research
- Puzanov I.
- Diab A.
- Abdallah K.
- Bingham C.O.
- Brogdon C.
- Dadu R.
- et al.
Conclusion
CRediT authorship contribution statement
Declaration of Competing Interest
Acknowledgments
Appendix A. Supplementary material
- Supplementary data 1
References
- DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1.Clin Cancer Res. 2016; 22: 5097-5108
- The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy.Chem Pharm Bull (Tokyo). 2019; 67: 173-185
- Increased expression of cathepsin L: A novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients.PLoS One. 2014; 9: e112136
- Cathepsin B: Multiple roles in cancer.Proteomics Clin Appl. 2014; 8: 427-437
- Trastuzumab deruxtecan in previously treated HER2-positive breast cancer.N Engl J Med. 2020; 382: 610-621
- Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer.N Engl J Med. 2022; 386: 241-251
Cortés J, Kim SB, Chung WP, Im S, Park YH, Hegg R, et al. Trastuzumab deruxtecan (T-DXd) vs Trastuzumab emtansine (T-DM1) in patients With HER2+ metastatic breast cancer: Results of the randomized, phase 3 study DESTINY breast03. presented at: ESMO congress; September 16-21, 2021.
- Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer.N Engl J Med. 2020; 382: 2419-2430
Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Primary analysis of a phase 2 single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. Presented at: ESMO Congress; September 16-21, 2021.
Enhertu (trastuzumab deruxtecan). Summary of product characteristics. Daiichi Sankyo Europe GmbH; 2021.
Enhertu (trastuzumab deruxtecan). Summary of product characteristics. Daiichi Sankyo Company, Limited; 2020.
Enhertu (fam-trastuzumab deruxtecan-nxki). Prescribing information. Daiichi Sankyo, Inc.; 2021.
Enhertu (trastuzumab deruxtecan). Product monograph. Daiichi Sankyo Company, AstraZeneca Canada Inc; 2021.
ClinicalTrials.gov. A phase 2 study of T-DXd in patients with selected HER2 expressing tumors (DPT02). https://clinicaltrials.gov/ct2/show/NCT04482309 (accessed May 25 2021).
ClinicalTrials.gov. A Study of T-DXd for the treatment of solid tumors harboring HER2 activating mutations (DPT01). https://clinicaltrials.gov/ct2/show/NCT04639219 (accessed May 19 2021).
ClinicalTrials.gov. Trastuzumab deruxtecan in participants with HER2-overexpressing advanced or metastatic colorectal cancer (DESTINY-CRC02). https://clinicaltrials.gov/ct2/show/NCT04744831 (accessed May 19 2021).
- Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.J Clin Oncol. 2020; 38 (Abstract 9504)
ClinicalTrials.gov. Trastuzumab deruxtecan (DS-8201a) versus investigator's choice for HER2-low breast cancer that has spread or cannot be surgically removed [DESTINY-Breast04]. https://clinicaltrials.gov/ct2/show/NCT03734029 (accessed May 19 2021).
ClinicalTrials.gov. Study of trastuzumab deruxtecan (T-DXd) vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer (DB-06). https://clinicaltrials.gov/ct2/show/NCT04494425 (accessed May 19 2021).
ClinicalTrials.gov. Trastuzumab deruxtecan (T-DXd) with or without pertuzumab versus taxane, trastuzumab and pertuzumab in HER2-positive metastatic breast cancer (DESTINY-Breast09). https://clinicaltrials.gov/ct2/show/NCT04784715 (accessed June 3 2021).
ClinicalTrials.gov. Ph1b/2 study of the safety and efficacy of T-DXd combinations in advanced HER2+ gastric cancer (DESTINY-Gastric03) (DG-03). https://clinicaltrials.gov/ct2/show/NCT04379596 (accessed June 10 2021).
- Targeting HER2 with trastuzumab deruxtecan: A dose-expansion, phase I study in multiple advanced solid tumors.Cancer Discov. 2020; 10: 688-701
- Drug-induced interstitial lung disease: A systematic review.J Clin Med. 2018; 7: 356https://doi.org/10.3390/jcm7100356
- Deciphering drug-induced interstitial lung disease: A mechanistic approach.Applied Radiology. 2016; 45: 9
- Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: A review.JAMA Oncol. 2021; 7: 1873https://doi.org/10.1001/jamaoncol.2021.3595
- Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.Breast Cancer Res Treat. 2020; 183: 23-39
- Interstitial Lung Disease.StatPearls Treasure Island (FL): StatPearls Publishing LLC. 2021; (https://www.ncbi.nlm.nih.gov/books/NBK541084/)
Meyer KC. Diagnosis and management of interstitial lung disease. Transl Respir Med 2014;2:4.
- Management of chronic respiratory failure in interstitial lung diseases: Overview and clinical insights.Int J Med Sci. 2019; 16: 967-980
- Drug-induced interstitial lung disease: Mechanisms and best diagnostic approaches.Respir Res. 2012; 13: 39https://doi.org/10.1186/1465-9921-13-39
- Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: A position paper from the Fleischner Society.Chest. 2021; 159: 1107-1125
- An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.Am J Respir Crit Care Med. 2013; 188: 733-748
- Interstitial lung disease as an adverse drug reaction in Japan: Exploration of regulatory actions as a basis for high reporting.Drug Saf. 2020; 43: 1121-1131
US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0, 2017.
- Radiation-induced lung injury: Current evidence.BMC Pulm Med. 2021; 21: 9
- The genetic and environmental causes of pulmonary fibrosis.Proc Am Thorac Soc. 2012; 9: 120-125
- The role of infection in interstitial lung diseases: A review.Chest. 2017; 152: 842-852
- Consensus statement for the diagnosis and treatment of drug-induced lung injuries.Respir Investig. 2013; 51: 260-277
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.Eur Respir J. 2017; 50
- Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.Cancer Sci. 2020; 111: 4636-4645
- Trastuzumab deruxtecan: Changing the destiny of HER2 expressing solid tumors.Int J Mol Sci. 2021; 22: 4774https://doi.org/10.3390/ijms22094774
- Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications.Mol Biol Int. 2014; 2014 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170925/): 1-9
- Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.Oncogene. 1990; 5: 953-962
- 03 Datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study.J Thorac Oncol. 2021; 16: S106-S107
- Interstitial lung disease associated with trastuzumab monotherapy: A report of 3 cases.Mol Clin Oncol. 2017; 6: 229-232
KADCYLA® (ado-trastuzumab emtansine). Prescribing information. Genentech, Inc.; 2020.
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: A phase 1 dose-escalation and dose-expansion study.Lancet Oncol. 2019; 20: 1124-1135
- Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.J Clin Oncol. 2004; 22: 909-918
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2017; 28: iv119-iv142
- Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: A single-institution retrospective study.Sci Rep. 2020; 10https://doi.org/10.1038/s41598-020-70743-2
- Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials.Chest. 2017; 152: 271-281
- Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: A multicenter prospective study.J Thorac Oncol. 2020; 15: 1317-1327
- Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.Lung Cancer. 2017; 104: 111-118
- Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis.JAMA Oncol. 2016; 2: 1607-1616
ClinicalTrials.gov. DS8201a and pembrolizumab in participants with locally advanced/metastatic breast or non-small cell lung cancer. https://clinicaltrials.gov/ct2/show/NCT04042701 (accessed February 17 2022).
ClinicalTrials.gov. A phase 1b/2 study of T-DXd combinations in HER2-positive metastatic breast cancer (DB-07). https://clinicaltrials.gov/ct2/show/NCT04538742 (accessed February 17 2022).
ClinicalTrials.gov. A phase 1b study of T-DXd combinations in HER2-low advanced or metastatic breast cancer (DB-08). https://clinicaltrials.gov/ct2/show/NCT04556773 (accessed February 17 2022).
ClinicalTrials.gov. A study of novel anti-cancer agents in patients with metastatic triple negative breast cancer (BEGONIA). https://clinicaltrials.gov/ct2/show/NCT03742102 (accessed February 17 2022).
ClinicalTrials.gov. Phase Ib study of the safety of T-DXd and durvalumab with chemotherapy in advanced or metastatic HER2+ non-squamous NSCLC (DL03). https://clinicaltrials.gov/ct2/show/NCT04686305 (accessed February 17 2022).
ClinicalTrials.gov. Phase II umbrella study of novel anti-cancer agents in patients with NSCLC who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON). https://clinicaltrials.gov/ct2/show/NCT03334617 (accessed February 17 2022).
US Food and Drug Administration. Center for drug evaluation and research. NDA/BLA multi-disciplinary review and evaluation {BLA 761139} ENHERTU (fam-trastuzumab deruxtecan-nxki) 2019.
Powell CA, Modi S, Iwata H, Takahashi S, Smit EF, Siena S, et al. Pooled analysis of drug-related interstitial lung disease in 8 single-arm trastuzumab deruxtecan studies. Presented at: AACR Annual Meeting 2021; April 10-15, 2021; Virtual. [abstract CT167].
Powell CA, Modi S, Iwata H, Takahashi S, Nie K, Qin A, et al. Analysis of study drug-related interstitial lung disease in patients with HER2+ metastatic breast cancer treated with trastuzumab deruxtecan. Presented at: ESMO Breast Cancer Virtual Congress; May 5-8, 2021.
- Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.Cancer Sci. 2014; 105: 1584-1590
- Exposure-response relationships in patients with HER2-positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan.Clin Pharmacol Ther. 2021; 110: 986-996
- Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.Lung Cancer. 2018; 123: 60-69
- The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis.Lung Cancer. 2019; 132: 79-86
- Population pharmacokinetics of trastuzumab deruxtecan in patients with HER2-positive breast cancer and other solid tumors.Clin Pharmacol Ther. 2021; 109: 1314-1325
- Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis.Ann Rheum Dis. 2019; 78: 1144-1146
- Non-invasive diagnosis of early pulmonary disease in PECAM-deficient mice using infrared pulse oximetry.Exp Mol Pathol. 2009; 87: 152-158
- The uses of overnight pulse oximetry.Lung India. 2020; 37 (https://journals.lww.com/lungindia/Fulltext/2020/37020/The_uses_of_overnight_pulse_oximetry.11.aspx): 151-157
- Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease.Eur Respir J. 2017; 49
- Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD.Respirology. 2018; 23: 392-398
- A multidisciplinary toxicity team for cancer immunotherapy-related adverse events.J Natl Compr Canc Netw. 2019; 17: 712-720
- Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline.Am J Respir Crit Care Med. 2018; 198: e44-e68
- Deep learning in interstitial lung disease-how long until daily practice.Eur Radiol. 2020; 30: 6285-6292
- Drug-related pneumonitis in cancer treatment during the COVID-19 era.Cancers. 2021; 13: 1052https://doi.org/10.3390/cancers13051052
- Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma.World J Gastroenterol. 2005; 11: 6607-6612
- Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Oncology Clinical Practice Guideline.J Clin Oncol. 2018; 36: 1714-1768
- Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.J Immunother Cancer. 2017; 5https://doi.org/10.1186/s40425-017-0300-z
- An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.Am J Respir Crit Care Med. 2011; 183: 96-128
- Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.Anticancer Drugs. 2011; 22: 563-568
- Preexisting interstitial lung disease and lung injury associated with irinotecan in patients with neoplasms.Anticancer Res. 2018; 38: 5937-5941
- Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease.Cancer Chemother Pharmacol. 2015; 76: 499-505
- Computer-aided diagnosis of pulmonary fibrosis using deep learning and CT images.Invest Radiol. 2019; 54: 627-632
- Exploring the ability of electronic nose technology to recognize interstitial lung diseases (ILD) by non-invasive breath screening of exhaled volatile compounds (VOC): A pilot study from the european IPF registry (eurIPFreg) and biobank.J Clin Med. 2019; 8: 1698https://doi.org/10.3390/jcm8101698
Interstitial Lung Disease. ATS clinical practice guidelines & statements. https://www.thoracic.org/education-center/ild/resources.html (accessed February 22 2022).
- Trastuzumab deruxtecan in HER2-overexpressing metastatic non-small cell lung cancer: Interim results of DESTINY-Lung01.J Thorac Oncol. 2021; 2021: S109-S110
Article Info
Publication History
Identification
Copyright
User License
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy